Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib plus Caelyx for trastuzumab-failed advanced metastatic breast cancer
2008-004530-25Phase 2Terminated
- Sponsor
- AGMT
- Start
- Feb 2009
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin and lapatinib in breast cancer, sponsored by AGMT. Primary endpoints: Overall response rate and Safety profile. Started Feb 2009; status: terminated.
02
Drugs
pegylated liposomal doxorubicinlapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-004530-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004530-25.